Zobrazeno 1 - 2
of 2
pro vyhledávání: '"Lars R. Fransecky"'
Autor:
Lars R. Fransecky, Hubert Serve, Nicola Goekbuget, Andreas Viardot, Walter Fiedler, Mustafa Kondakci, Julian Hermann, Max S. Topp, Sonja Martin, Simon Raffel, Knut Wendelin, Nael Alakel, Stefan Schwartz, Wolfram Jung, Ralph Wäsch, Daniela Heidenreich, Marion Subklewe, Monika Brüggemann, Wiba Keke Wermann, Matthias Stelljes, Andreas Hüttmann, Vladan Vucinic, Ralf C. Bargou, Christoph Faul
Publikováno v:
Blood. 136:39-40
MRD in ALL is defined as the detection of leukemic cells in bone marrow below the microscopic threshold in complete remission (CR). Patients (pts) with molecular failure (MolFail) or molecular relapse (MolRel) after induction/consolidation therapy ar
Autor:
Carsten Müller-Tidow, Christoph Röllig, Juergen Novotny, Hubert Serve, Claudia D. Baldus, Karsten Spiekermann, Richard Noppeney, Matthias Stelljes, Uwe Platzbecker, Marika Mende, Ulrich Dührsen, Jan Moritz Middeke, Katja Sockel, Christian Thiede, Schumacher Martin, Katharina Götze, Michael Kramer, Gerhard Ehninger, Mathias Hänel, Anne Sophie Kubasch, Johannes Schetelig, Antje Schubert, Christoph Groth, Lars R. Fransecky, Martin Bornhäuser, Marion Subklewe, Alwin Krämer, Anke Mütherig, Regina Herbst, Tilmann Bochtler, Gesine Bug, Dominik Wolf
Publikováno v:
Blood. 134:644-644
Background: Measurable residual disease (MRD) can identify patients (pts) with myelodysplastic syndrome (MDS) or acute myeloid leukemia (AML) in complete hematological remission (CR) at high risk of relapse even after allogeneic hematopoietic stem ce